User profiles for Benjamin Blyth
Benjamin BlythPeter MacCallum Cancer Centre Verified email at petermac.org Cited by 1178 |
[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint …
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint …
Radiation-induced bystander effects: what are they, and how relevant are they to human radiation exposures?
BJ Blyth, PJ Sykes - Radiation research, 2011 - meridian.allenpress.com
The term radiation-induced bystander effect is used to describe radiation-induced biological
changes that manifest in unirradiated cells remaining within an irradiated cell population. …
changes that manifest in unirradiated cells remaining within an irradiated cell population. …
Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity
…, L MacPherson, EN Wainwright, B Liddicoat, BJ Blyth… - Cancer Discovery, 2023 - AACR
This work demonstrates that METTL3 inhibition stimulates a cell-intrinsic interferon response
through dsRNA formation. This immunomodulatory mechanism is distinct from current …
through dsRNA formation. This immunomodulatory mechanism is distinct from current …
[HTML][HTML] Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer
The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging
and therapy of prostate cancer using bombesin peptides that bind to the receptor with high …
and therapy of prostate cancer using bombesin peptides that bind to the receptor with high …
[HTML][HTML] Imaging immunity in patients with cancer using positron emission tomography
Immune checkpoint inhibitors and related molecules can achieve tumour regression, and
even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis. …
even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis. …
[HTML][HTML] A deep learning model to automate skeletal muscle area measurement on computed tomography images
Background Muscle wasting (Sarcopenia) is associated with poor outcomes in cancer patients.
Early identification of sarcopenia can facilitate nutritional and exercise intervention. Cross…
Early identification of sarcopenia can facilitate nutritional and exercise intervention. Cross…
Radiation therapy-induced metastasis: radiobiology and clinical implications
Radiation therapy is an effective means of achieving local control in a wide range of primary
tumours, with the reduction in the size of the tumour(s) thought to mediate the observed …
tumours, with the reduction in the size of the tumour(s) thought to mediate the observed …
Potential screening assays for individual radiation sensitivity and susceptibility and their current validation state
M Gomolka, B Blyth, M Bourguignon… - … Journal of Radiation …, 2020 - Taylor & Francis
Purpose: The workshop on ‘Individual Radiosensitivity and Radiosusceptibility’ organized by
MELODI and CONCERT on Malta in 2018, evaluated the current state of assays to identify …
MELODI and CONCERT on Malta in 2018, evaluated the current state of assays to identify …
[HTML][HTML] Clinical and functional assays of radiosensitivity and radiation-induced second cancer
Whilst the near instantaneous physical interaction of radiation energy with living cells leaves
little opportunity for inter-individual variation in the initial yield of DNA damage, all the …
little opportunity for inter-individual variation in the initial yield of DNA damage, all the …
[HTML][HTML] A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapy
…, T Gulati, KJ Simpson, RW Tothill, B Blyth… - Theranostics, 2023 - ncbi.nlm.nih.gov
Peptide receptor radionuclide therapy (PRRT) using 177 Lutetium-DOTA-octreotate (LuTate)
for neuroendocrine tumours (NET) is now an approved treatment available in many …
for neuroendocrine tumours (NET) is now an approved treatment available in many …